期刊文献+

羟基喜树碱对肠癌细胞体外作用的研究 被引量:4

EFFECT OF HYDROXY CAMPTOTHECIN ON COLORECTAL CARCINOMA CELLS IN VITRO
暂未订购
导出
摘要 目的探讨羟基喜树碱对肠癌细胞的体外作用。方法 :采用改良的MTT法检测了 78例肠癌细胞对 5种化疗药物的体外敏感性。结果 :78例肠癌细胞对化疗药物的敏感性 ,由高到低依次为羟基喜树碱 (HCPT)、5-氟脲嘧啶 (5 -Fu)、丝裂霉素 (MMC)、平阳霉素 (PYM)、长春新碱 (VCR)。HCPT和 5 -Fu的敏感性差异无显著性 (P >0 .0 5 ) ,但均明显高于MMC、PYM及VCR(均P <0 .0 0 1) ,对 5 -Fu不敏感的病例中 ,5 7.8%对HCPT敏感或中度敏感。结论 :HCPT和 5 -Fu皆可作为肠癌的首选化疗药物 ,如果 5 -Fu耐药 ,则可选用HCPT。正确取材是MTT法成功的关键。 Objective:To explore the effect of hydroxy camptothecin (HCPT) on colorectal carcinoma cells in vitro. Method:The sensitivity of colorectal carcinoma cells to chemotherapeutic agents was detected in 78 cases with reformed MTT method.Results:The colorectal carcinoma cells of 78 cases showed different sensitivity arrayed from strong to mild to following five chemotherapeutic agents:HCPT,5-Fu,MMC,PYM and VCR.The sensitivity of those cells to HCPT and 5-Fu showed no difference( P >0.05) and was stronger than that of MMC,PYM and VCR( P <0.01).Among the cases who showed no sensitivity to 5-Fu,57.8% were strong or averagely sensitive to HCPT. Conclusions:HCPT and 5-Fu can be used as the preferred chemotherapeutic agents.HCPT may be used if the cells do not show sensitivity to 5-Fu.The key of MTT method is correct biopsy.
出处 《中国现代医学杂志》 CAS CSCD 2002年第6期63-64,共2页 China Journal of Modern Medicine
关键词 羟基喜树碱 肠癌 药物敏感试验 肠癌细胞 体外作用 Hydroxy Camptothecin Colorectal Carcinoma Sensitivity test of Medicine
  • 相关文献

参考文献4

  • 1Rowe PM.Camptothecin:new enthusiasm for and old drug[J].Lancet,1995;347:892~896
  • 2王灏,胡伟国.羟基喜树碱治疗进展期大肠癌[J].中国癌症杂志,1998,8(1):63-64. 被引量:27
  • 3Wiseman IR,Markham A.A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.Drugs,1996;52(4):606~623
  • 4Blerberg H.Role of chemotherapy for advanced colorectal cancer:new opportunitees.Semin Oncol,1996;23:42~50

二级参考文献16

  • 1Rowe PM. Camptothecins: new enthusiasm for an old drug.Lancet, 1995,347:892.
  • 2Slichenmyer WJ, Rowinsky EK, Donehower RC, et al.The current status of camptothecin analogues as antitumor agents,J Natl Cancer Inst,1993,85:271.
  • 3Bleiberg H. Colorectal cancer: the challenge, Eut J Cancer,1996,32(A Suppl 5):S2.
  • 4Labianca R, Pessi A, Facendola G, et al. Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer:a critical review of comparative studies. Eur J Cancer,1996,32(A Suppl5):S7.
  • 5Shimada Y, Rougier P, Pitot H. Efficacy of CPT-11(irinotecan) ad a single agent in metastatic colorectal cancer.Eur J Cancer,1996,32(A Suppl3):S13.
  • 6Wiseman LR, Markham A. Irinotecan. A review of its pharma cological properties and clinical efficacy in the management of advanced colorectal cancer.Drugs,1996,52:606.
  • 7Armand JP, Ducreux M, Mahjoubi M, et al. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer,1995,31(A Suppl 3):1283.
  • 8Cunningham D. Current status of colorectal cancer:CPT-11(irinotecan), a therapeutic innovation. Eur J Cancer, 1996,32(A Suppl 3):S1.
  • 9Rougier P, Bugat R. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin Oncol,1996,23(1Suppl3):34.
  • 10Saltz L, Shimada Y, Khayat D. CPT-11 (irinotecan)and 5-fluorouracil:a promising combination for therapy of colorectal cancer. Eur J Cancer, 1996,32(A Suppl 3):S24.

共引文献26

同被引文献34

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部